标题
Review article: HCV genotype 3 - the new treatment challenge
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 39, Issue 7, Pages 686-698
出版商
Wiley
发表日期
2014-02-25
DOI
10.1111/apt.12646
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Associations of chronic hepatitis C with metabolic and cardiac outcomes
- (2013) Z. M. Younossi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6
- (2013) J. M. Wantuck et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Emerging treatments for hepatitis C
- (2013) Robert Flisiak et al. EXPERT OPINION ON EMERGING DRUGS
- Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
- (2013) David Alan Herbst et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection
- (2013) D Alan Herbst et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection
- (2013) Maribel Rodríguez-Torres Expert Review of Anti-Infective Therapy
- New horizons in hepatitis C antiviral therapy with direct-acting antivirals
- (2013) Alessio Aghemo et al. HEPATOLOGY
- Is genotype 3 of the hepatitis C virus the new villain?
- (2013) Nicolas Goossens et al. HEPATOLOGY
- Molecular Epidemiology and Genetic History of Hepatitis C Virus Subtype 3a Infection in Thailand
- (2013) Srunthron Akkarathamrongsin et al. INTERVIROLOGY
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- (2013) Adriaan J. van der Meer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
- (2013) G.J. Dore et al. JOURNAL OF HEPATOLOGY
- Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3
- (2013) Marcelo O. Silva et al. JOURNAL OF HEPATOLOGY
- Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
- (2013) Vincenza Conteduca et al. JOURNAL OF INFECTION
- Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
- (2013) E. B. Tapper et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- HCV direct-acting antiviral agents: the best interferon-free combinations
- (2013) Raymond Schinazi et al. LIVER INTERNATIONAL
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
- (2013) Edward J. Gane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism
- (2012) J. A. del Campo et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The role of viral and host genetics in natural history and treatment of chronic HCV infection
- (2012) Joseph S. Doyle et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner
- (2012) Paul J. Clark et al. HEPATOLOGY
- 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
- (2012) M. Sulkowski et al. JOURNAL OF HEPATOLOGY
- Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study
- (2012) Christophe Moreno et al. JOURNAL OF HEPATOLOGY
- Steatosis and insulin resistance in response to treatment of chronic hepatitis C
- (2012) F. Negro JOURNAL OF VIRAL HEPATITIS
- Meta-analysis: insulin resistance and sustained virological response in hepatitis C
- (2011) M. Eslam et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3
- (2011) Samir R. Shah et al. Clinical Gastroenterology and Hepatology
- Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
- (2011) Graham R. Foster et al. GASTROENTEROLOGY
- ‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?
- (2011) Andres Duarte-Rojo et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
- (2011) JOURNAL OF HEPATOLOGY
- Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR
- (2011) L. Restivo et al. JOURNAL OF VIRAL HEPATITIS
- HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
- (2011) G. Nkontchou et al. JOURNAL OF VIRAL HEPATITIS
- Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis
- (2011) A. Probst et al. JOURNAL OF VIRAL HEPATITIS
- Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies
- (2011) Shiv K. Sarin et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin
- (2010) Moises Diago et al. HEPATOLOGY
- Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR- in Huh-7 cells
- (2010) V. Pazienza et al. JOURNAL OF GENERAL VIROLOGY
- 37 SUSTAINED VIROLOGIC RESPONSE (SVR) FOLLOWING RG7128 1500MG BID/PEG-IFN/RBV FOR 28 DAYS IN HCV GENOTYPE 2/3 PRIOR NON-RESPONDERS
- (2010) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3
- (2010) Alessandra Mangia et al. JOURNAL OF HEPATOLOGY
- Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin
- (2010) Thomas-Matthias Scherzer et al. JOURNAL OF HEPATOLOGY
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients
- (2009) Robert Flisiak et al. HEPATOLOGY
- Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
- (2009) Pierre-Yves Bochud et al. JOURNAL OF HEPATOLOGY
- Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
- (2008) A. ANDRIULLI et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission
- (2008) Muhammad Idrees et al. BMC INFECTIOUS DISEASES
- Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
- (2008) Martin Lagging et al. HEPATOLOGY
- The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
- (2008) Robert Flisiak et al. HEPATOLOGY
- Hepatitis C genotype 4: What we know and what we don't yet know
- (2008) Sanaa M. Kamal et al. HEPATOLOGY
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
- Changing HCV genotypes distribution in Poland—Relation to source and time of infection
- (2008) Slawomir Chlabicz et al. JOURNAL OF CLINICAL VIROLOGY
- 774 BASELINE AND ON-TREATMENT FACTORS ASSOCIATED WITH HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH AND WITHOUT CIRRHOSIS FOLLOWING TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN
- (2008) S. Bruno et al. JOURNAL OF HEPATOLOGY
- Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C
- (2008) Manuel Romero-Gómez et al. JOURNAL OF HEPATOLOGY
- Specific Polymorphisms in Hepatitis C Virus Genotype 3 Core Protein Associated with Intracellular Lipid Accumulation
- (2008) Ravi Jhaveri et al. JOURNAL OF INFECTIOUS DISEASES
- Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006
- (2008) Francois Roman et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis
- (2007) Rami Moucari et al. GASTROENTEROLOGY
- Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3
- (2007) Hossein Poustchi et al. JOURNAL OF HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now